Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Management of glomerular proteinuria: a commentary.

Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA.

J Am Soc Nephrol. 2003 Dec;14(12):3217-32. Review.

2.

Renoprotection: one or many therapies?

Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH.

Kidney Int. 2001 Apr;59(4):1211-26. Review.

4.

Therapeutic measures in proteinuric nephropathy.

Praga M.

Kidney Int Suppl. 2005 Dec;(99):S137-41. Review.

PMID:
16336567
5.

[Are all antihypertensive drugs renoprotective?].

Wolf S, Risler T.

Herz. 2004 May;29(3):248-54. Review. German.

PMID:
15167950
6.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.

Am J Kidney Dis. 2006 Jul;48(1):8-20. Review.

PMID:
16797382
7.

The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).

Luno J, Praga M, de Vinuesa SG.

Curr Pharm Des. 2005;11(10):1291-300. Review.

PMID:
15853685
8.

Titrating for antiproteinuric effect: the clue to renoprotection?

Navis G, de Zeeuw D.

J Hum Hypertens. 1996 Oct;10(10):669-73. Review.

PMID:
9004092
9.

Reversal of proteinuric renal disease and the emerging role of endothelin.

Barton M.

Nat Clin Pract Nephrol. 2008 Sep;4(9):490-501. doi: 10.1038/ncpneph0891. Epub 2008 Jul 22. Review.

PMID:
18648345
10.

Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN).

Remuzzi G, Chiurchiu C, Ruggenenti P.

Kidney Int Suppl. 2004 Nov;(92):S90-6. Review.

11.

Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results.

Lea JP, Brown DT, Lipkowitz M, Middleton J, Norris K; AASK Study Group.

Am J Cardiovasc Drugs. 2003;3(3):193-200. Review.

PMID:
14727931
12.

Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.

Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S250-4. Review.

13.

Antihypertensive therapy in the presence of proteinuria.

Sarafidis PA, Khosla N, Bakris GL.

Am J Kidney Dis. 2007 Jan;49(1):12-26. Review.

PMID:
17185142
14.

Clinical benefits of slowing the progression of renal failure.

Locatelli F, Del Vecchio L, Pozzoni P.

Kidney Int Suppl. 2005 Dec;(99):S152-6. Review.

PMID:
16336569
15.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

16.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
17.
18.

Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.

Chiurchiu C, Remuzzi G, Ruggenenti P.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S58-63. Review.

19.
20.

Aldosterone and progression of kidney disease.

Cortinovis M, Perico N, Cattaneo D, Remuzzi G.

Ther Adv Cardiovasc Dis. 2009 Apr;3(2):133-43. doi: 10.1177/1753944708100409. Epub 2009 Jan 26. Review.

PMID:
19171691

Supplemental Content

Support Center